Canada markets close in 3 hours 39 minutes
  • S&P/TSX

    21,004.08
    -169.37 (-0.80%)
     
  • S&P 500

    4,577.45
    +2.66 (+0.06%)
     
  • DOW

    35,664.66
    -92.22 (-0.26%)
     
  • CAD/USD

    0.8106
    +0.0034 (+0.42%)
     
  • CRUDE OIL

    82.66
    -1.99 (-2.35%)
     
  • BTC-CAD

    72,557.12
    -4,711.25 (-6.10%)
     
  • CMC Crypto 200

    1,410.24
    -64.09 (-4.35%)
     
  • GOLD FUTURES

    1,797.70
    +4.30 (+0.24%)
     
  • RUSSELL 2000

    2,273.03
    -23.05 (-1.00%)
     
  • 10-Yr Bond

    1.5470
    -0.0720 (-4.45%)
     
  • NASDAQ

    15,327.58
    +91.86 (+0.60%)
     
  • VOLATILITY

    16.03
    +0.05 (+0.31%)
     
  • FTSE

    7,253.27
    -24.35 (-0.33%)
     
  • NIKKEI 225

    29,098.24
    -7.77 (-0.03%)
     
  • CAD/EUR

    0.6982
    +0.0025 (+0.36%)
     

Global Myasthenia Gravis Treatment Market to Reach $2 Billion by 2027

·26 min read

Abstract: - Global Myasthenia Gravis Treatment Market to Reach $2 Billion by 2027. - Amid the COVID-19 crisis, the global market for Myasthenia Gravis Treatment estimated at US$1.

New York, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Myasthenia Gravis Treatment Industry" - https://www.reportlinker.com/p06032287/?utm_source=GNW
3 Billion in the year 2020, is projected to reach a revised size of US$2 Billion by 2027, growing at a CAGR of 6.3% over the analysis period 2020-2027. Medication, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$1.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Surgery segment is readjusted to a revised 4.7% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $352 Million, While China is Forecast to Grow at 9.7% CAGR
- The Myasthenia Gravis Treatment market in the U.S. is estimated at US$352 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$430 Million by the year 2027 trailing a CAGR of 9.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 5.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.
- Other Treatment Types Segment to Record 3.3% CAGR
- In the global Other Treatment Types segment, USA, Canada, Japan, China and Europe will drive the 2.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$47.6 Million in the year 2020 will reach a projected size of US$58.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$270.2 Million by the year 2027, while Latin America will expand at a 4.2% CAGR through the analysis period.

- Select Competitors (Total 34 Featured) -

  • AbbVie Inc.

  • Alexion Pharmaceutical Inc.

  • Avadel Pharmaceuticals plc

  • Bausch Health Companies Inc.

  • Baxter International, Inc.

  • CSL Behring

  • F. Hoffmann-La Roche Ltd.

  • GlaxoSmithKline plc

  • Grifols SA

  • Novartis AG

  • Pfizer, Inc.

  • Shire plc

  • Takeda Pharmaceutical Company Limited

  • Valeant Pharmaceuticals International, Inc.




Read the full report: https://www.reportlinker.com/p06032287/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Myasthenia Gravis
Treatment by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Myasthenia Gravis Treatment
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Myasthenia Gravis
Treatment by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2012,
2020 & 2027

Table 4: World Current & Future Analysis for Medication by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Medication by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Medication by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Surgery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Surgery by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Surgery by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Other Treatment
Types by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Other Treatment Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Other Treatment Types
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Hospitals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Clinics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Clinics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Clinics by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 22: USA Current & Future Analysis for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 23: USA Historic Review for Myasthenia Gravis Treatment
by Treatment Type - Medication, Surgery and Other Treatment
Types Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 24: USA 15-Year Perspective for Myasthenia Gravis
Treatment by Treatment Type - Percentage Breakdown of Value
Sales for Medication, Surgery and Other Treatment Types for the
Years 2012, 2020 & 2027

Table 25: USA Current & Future Analysis for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 26: USA Historic Review for Myasthenia Gravis Treatment
by End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 27: USA 15-Year Perspective for Myasthenia Gravis
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 &
2027

CANADA
Table 28: Canada Current & Future Analysis for Myasthenia
Gravis Treatment by Treatment Type - Medication, Surgery and
Other Treatment Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 29: Canada Historic Review for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 30: Canada 15-Year Perspective for Myasthenia Gravis
Treatment by Treatment Type - Percentage Breakdown of Value
Sales for Medication, Surgery and Other Treatment Types for the
Years 2012, 2020 & 2027

Table 31: Canada Current & Future Analysis for Myasthenia
Gravis Treatment by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 32: Canada Historic Review for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 33: Canada 15-Year Perspective for Myasthenia Gravis
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 &
2027

JAPAN
Table 34: Japan Current & Future Analysis for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 35: Japan Historic Review for Myasthenia Gravis Treatment
by Treatment Type - Medication, Surgery and Other Treatment
Types Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 36: Japan 15-Year Perspective for Myasthenia Gravis
Treatment by Treatment Type - Percentage Breakdown of Value
Sales for Medication, Surgery and Other Treatment Types for the
Years 2012, 2020 & 2027

Table 37: Japan Current & Future Analysis for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 38: Japan Historic Review for Myasthenia Gravis Treatment
by End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 39: Japan 15-Year Perspective for Myasthenia Gravis
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 &
2027

CHINA
Table 40: China Current & Future Analysis for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 41: China Historic Review for Myasthenia Gravis Treatment
by Treatment Type - Medication, Surgery and Other Treatment
Types Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 42: China 15-Year Perspective for Myasthenia Gravis
Treatment by Treatment Type - Percentage Breakdown of Value
Sales for Medication, Surgery and Other Treatment Types for the
Years 2012, 2020 & 2027

Table 43: China Current & Future Analysis for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 44: China Historic Review for Myasthenia Gravis Treatment
by End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 45: China 15-Year Perspective for Myasthenia Gravis
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 &
2027

EUROPE
Table 46: Europe Current & Future Analysis for Myasthenia
Gravis Treatment by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 47: Europe Historic Review for Myasthenia Gravis
Treatment by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 48: Europe 15-Year Perspective for Myasthenia Gravis
Treatment by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2012, 2020 & 2027

Table 49: Europe Current & Future Analysis for Myasthenia
Gravis Treatment by Treatment Type - Medication, Surgery and
Other Treatment Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Europe Historic Review for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Europe 15-Year Perspective for Myasthenia Gravis
Treatment by Treatment Type - Percentage Breakdown of Value
Sales for Medication, Surgery and Other Treatment Types for the
Years 2012, 2020 & 2027

Table 52: Europe Current & Future Analysis for Myasthenia
Gravis Treatment by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 53: Europe Historic Review for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 54: Europe 15-Year Perspective for Myasthenia Gravis
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 &
2027

FRANCE
Table 55: France Current & Future Analysis for Myasthenia
Gravis Treatment by Treatment Type - Medication, Surgery and
Other Treatment Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 56: France Historic Review for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 57: France 15-Year Perspective for Myasthenia Gravis
Treatment by Treatment Type - Percentage Breakdown of Value
Sales for Medication, Surgery and Other Treatment Types for the
Years 2012, 2020 & 2027

Table 58: France Current & Future Analysis for Myasthenia
Gravis Treatment by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 59: France Historic Review for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 60: France 15-Year Perspective for Myasthenia Gravis
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 &
2027

GERMANY
Table 61: Germany Current & Future Analysis for Myasthenia
Gravis Treatment by Treatment Type - Medication, Surgery and
Other Treatment Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 62: Germany Historic Review for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 63: Germany 15-Year Perspective for Myasthenia Gravis
Treatment by Treatment Type - Percentage Breakdown of Value
Sales for Medication, Surgery and Other Treatment Types for the
Years 2012, 2020 & 2027

Table 64: Germany Current & Future Analysis for Myasthenia
Gravis Treatment by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 65: Germany Historic Review for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 66: Germany 15-Year Perspective for Myasthenia Gravis
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 &
2027

ITALY
Table 67: Italy Current & Future Analysis for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 68: Italy Historic Review for Myasthenia Gravis Treatment
by Treatment Type - Medication, Surgery and Other Treatment
Types Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 69: Italy 15-Year Perspective for Myasthenia Gravis
Treatment by Treatment Type - Percentage Breakdown of Value
Sales for Medication, Surgery and Other Treatment Types for the
Years 2012, 2020 & 2027

Table 70: Italy Current & Future Analysis for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 71: Italy Historic Review for Myasthenia Gravis Treatment
by End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 72: Italy 15-Year Perspective for Myasthenia Gravis
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 &
2027

UNITED KINGDOM
Table 73: UK Current & Future Analysis for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 74: UK Historic Review for Myasthenia Gravis Treatment by
Treatment Type - Medication, Surgery and Other Treatment Types
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 75: UK 15-Year Perspective for Myasthenia Gravis
Treatment by Treatment Type - Percentage Breakdown of Value
Sales for Medication, Surgery and Other Treatment Types for the
Years 2012, 2020 & 2027

Table 76: UK Current & Future Analysis for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 77: UK Historic Review for Myasthenia Gravis Treatment by
End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 78: UK 15-Year Perspective for Myasthenia Gravis
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 &
2027

SPAIN
Table 79: Spain Current & Future Analysis for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 80: Spain Historic Review for Myasthenia Gravis Treatment
by Treatment Type - Medication, Surgery and Other Treatment
Types Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 81: Spain 15-Year Perspective for Myasthenia Gravis
Treatment by Treatment Type - Percentage Breakdown of Value
Sales for Medication, Surgery and Other Treatment Types for the
Years 2012, 2020 & 2027

Table 82: Spain Current & Future Analysis for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 83: Spain Historic Review for Myasthenia Gravis Treatment
by End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 84: Spain 15-Year Perspective for Myasthenia Gravis
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 &
2027

RUSSIA
Table 85: Russia Current & Future Analysis for Myasthenia
Gravis Treatment by Treatment Type - Medication, Surgery and
Other Treatment Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 86: Russia Historic Review for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 87: Russia 15-Year Perspective for Myasthenia Gravis
Treatment by Treatment Type - Percentage Breakdown of Value
Sales for Medication, Surgery and Other Treatment Types for the
Years 2012, 2020 & 2027

Table 88: Russia Current & Future Analysis for Myasthenia
Gravis Treatment by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 89: Russia Historic Review for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 90: Russia 15-Year Perspective for Myasthenia Gravis
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 &
2027

REST OF EUROPE
Table 91: Rest of Europe Current & Future Analysis for
Myasthenia Gravis Treatment by Treatment Type - Medication,
Surgery and Other Treatment Types - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 92: Rest of Europe Historic Review for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 93: Rest of Europe 15-Year Perspective for Myasthenia
Gravis Treatment by Treatment Type - Percentage Breakdown of
Value Sales for Medication, Surgery and Other Treatment Types
for the Years 2012, 2020 & 2027

Table 94: Rest of Europe Current & Future Analysis for
Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 95: Rest of Europe Historic Review for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 96: Rest of Europe 15-Year Perspective for Myasthenia
Gravis Treatment by End-Use - Percentage Breakdown of Value
Sales for Hospitals, Clinics and Other End-Uses for the Years
2012, 2020 & 2027

ASIA-PACIFIC
Table 97: Asia-Pacific Current & Future Analysis for Myasthenia
Gravis Treatment by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 98: Asia-Pacific Historic Review for Myasthenia Gravis
Treatment by Geographic Region - Australia, India, South Korea
and Rest of Asia-Pacific Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 99: Asia-Pacific 15-Year Perspective for Myasthenia
Gravis Treatment by Geographic Region - Percentage Breakdown of
Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2020 & 2027

Table 100: Asia-Pacific Current & Future Analysis for
Myasthenia Gravis Treatment by Treatment Type - Medication,
Surgery and Other Treatment Types - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 101: Asia-Pacific Historic Review for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 102: Asia-Pacific 15-Year Perspective for Myasthenia
Gravis Treatment by Treatment Type - Percentage Breakdown of
Value Sales for Medication, Surgery and Other Treatment Types
for the Years 2012, 2020 & 2027

Table 103: Asia-Pacific Current & Future Analysis for
Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 104: Asia-Pacific Historic Review for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 105: Asia-Pacific 15-Year Perspective for Myasthenia
Gravis Treatment by End-Use - Percentage Breakdown of Value
Sales for Hospitals, Clinics and Other End-Uses for the Years
2012, 2020 & 2027

AUSTRALIA
Table 106: Australia Current & Future Analysis for Myasthenia
Gravis Treatment by Treatment Type - Medication, Surgery and
Other Treatment Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 107: Australia Historic Review for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 108: Australia 15-Year Perspective for Myasthenia Gravis
Treatment by Treatment Type - Percentage Breakdown of Value
Sales for Medication, Surgery and Other Treatment Types for the
Years 2012, 2020 & 2027

Table 109: Australia Current & Future Analysis for Myasthenia
Gravis Treatment by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 110: Australia Historic Review for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 111: Australia 15-Year Perspective for Myasthenia Gravis
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 &
2027

INDIA
Table 112: India Current & Future Analysis for Myasthenia
Gravis Treatment by Treatment Type - Medication, Surgery and
Other Treatment Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 113: India Historic Review for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 114: India 15-Year Perspective for Myasthenia Gravis
Treatment by Treatment Type - Percentage Breakdown of Value
Sales for Medication, Surgery and Other Treatment Types for the
Years 2012, 2020 & 2027

Table 115: India Current & Future Analysis for Myasthenia
Gravis Treatment by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 116: India Historic Review for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 117: India 15-Year Perspective for Myasthenia Gravis
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 &
2027

SOUTH KOREA
Table 118: South Korea Current & Future Analysis for Myasthenia
Gravis Treatment by Treatment Type - Medication, Surgery and
Other Treatment Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 119: South Korea Historic Review for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 120: South Korea 15-Year Perspective for Myasthenia
Gravis Treatment by Treatment Type - Percentage Breakdown of
Value Sales for Medication, Surgery and Other Treatment Types
for the Years 2012, 2020 & 2027

Table 121: South Korea Current & Future Analysis for Myasthenia
Gravis Treatment by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 122: South Korea Historic Review for Myasthenia Gravis
Treatment by End-Use - Hospitals, Clinics and Other End-Uses
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 123: South Korea 15-Year Perspective for Myasthenia
Gravis Treatment by End-Use - Percentage Breakdown of Value
Sales for Hospitals, Clinics and Other End-Uses for the Years
2012, 2020 & 2027

REST OF ASIA-PACIFIC
Table 124: Rest of Asia-Pacific Current & Future Analysis for
Myasthenia Gravis Treatment by Treatment Type - Medication,
Surgery and Other Treatment Types - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 125: Rest of Asia-Pacific Historic Review for Myasthenia
Gravis Treatment by Treatment Type - Medication, Surgery and
Other Treatment Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 126: Rest of Asia-Pacific 15-Year Perspective for
Myasthenia Gravis Treatment by Treatment Type - Percentage
Breakdown of Value Sales for Medication, Surgery and Other
Treatment Types for the Years 2012, 2020 & 2027

Table 127: Rest of Asia-Pacific Current & Future Analysis for
Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 128: Rest of Asia-Pacific Historic Review for Myasthenia
Gravis Treatment by End-Use - Hospitals, Clinics and Other
End-Uses Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 129: Rest of Asia-Pacific 15-Year Perspective for
Myasthenia Gravis Treatment by End-Use - Percentage Breakdown
of Value Sales for Hospitals, Clinics and Other End-Uses for
the Years 2012, 2020 & 2027

LATIN AMERICA
Table 130: Latin America Current & Future Analysis for
Myasthenia Gravis Treatment by Geographic Region - Argentina,
Brazil, Mexico and Rest of Latin America Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 131: Latin America Historic Review for Myasthenia Gravis
Treatment by Geographic Region - Argentina, Brazil, Mexico and
Rest of Latin America Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 132: Latin America 15-Year Perspective for Myasthenia
Gravis Treatment by Geographic Region - Percentage Breakdown of
Value Sales for Argentina, Brazil, Mexico and Rest of Latin
America Markets for Years 2012, 2020 & 2027

Table 133: Latin America Current & Future Analysis for
Myasthenia Gravis Treatment by Treatment Type - Medication,
Surgery and Other Treatment Types - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 134: Latin America Historic Review for Myasthenia Gravis
Treatment by Treatment Type - Medication, Surgery and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 135: Latin America 15-Year Perspective for Myasthenia
Gravis Treatment by Treatment Type - Percentage Breakdown of
Value Sales for Medication, Surgery and Other Treatment Types
for the Years 2012, 2020 & 2027

Table 136: Latin America Current & Future Analysis for
Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032287/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting